Contrasting Hologic (NASDAQ:HOLX) & Bionik Laboratories (OTCMKTS:BNKL)

Bionik Laboratories (OTCMKTS:BNKL) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Bionik Laboratories and Hologic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bionik Laboratories	N/A	N/A	N/A
Hologic	13.80%	20.13%	11.06%

Risk & Volatility

Bionik Laboratories has a beta of -1.68, indicating that its stock price is 268% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Valuation and Earnings

This table compares Bionik Laboratories and Hologic”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionik Laboratories	$1.80 million	N/A	-$4.95 million	($0.38)	N/A
Hologic	$4.10 billion	4.07	$565.70 million	$2.48	30.22

Hologic has higher revenue and earnings than Bionik Laboratories. Bionik Laboratories is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.7% of Hologic shares are owned by institutional investors. 34.7% of Bionik Laboratories shares are owned by company insiders. Comparatively, 1.9% of Hologic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Bionik Laboratories and Hologic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionik Laboratories	0	0	0	0	0.00
Hologic	0	13	5	0	2.28

Hologic has a consensus target price of $79.29, indicating a potential upside of 5.78%. Given Hologic’s stronger consensus rating and higher probable upside, analysts plainly believe Hologic is more favorable than Bionik Laboratories.

Summary

Hologic beats Bionik Laboratories on 11 of the 12 factors compared between the two stocks.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.

About Hologic

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.